ClinicalTrials.gg
CompletedNCT01358357PERSISTUpdated Sep 7, 2016Results posted

Bipolar Maintenance Study of Lurasidone Adjunctive to Lithium or Divalproex

A Phase 3 interventional study of Lurasidone and Placebo in Bipolar I Disorder, sponsored by Sumitomo Pharma America, Inc.. Completed at 105 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-09-07.

Sponsored by Sumitomo Pharma America, Inc. (part of Sumitomo Pharma Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
965
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a multi-center, randomized, placebo-controlled, flexible-dose, parallel-group study designed to evaluate the efficacy and safety of lurasidone (in combination with lithium or divalproex) for the maintenance treatment of bipolar I disorder in subjects with or without rapid cycling and /or psychotic features.

Read the detailed description

This study is to evaluate the efficacy and safety of lurasidone (in combination with lithium or divalproex) for the maintenance treatment of bipolar I disorder in subjects with or without rapid cycling and/or psychotic features.

02

Conditions studied

  • Bipolar I Disorder

Keywords

  • Lurasidone
  • Latuda
  • Bipolar I
03

In context

Lead sponsor

Sumitomo Pharma America, Inc. is the lead sponsor of 181 studies on the registry; 5 are open to participants now.

Of its 33 completed or terminated interventional studies of FDA-regulated products, 21 (64%) have results posted.

First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

Open-label Phase

  • 18 years of age or older
  • , 4th Ed., Text Revision (DSM-IV-TR) diagnosis of bipolar I disorder

    •≥ 1 manic, mixed manic, or depressed episode in past 2 years

  • YMRS or MADRS total score ≥ 14 if on lithium or divalproex; ≥ 18 if not on lithium or divalproex

Double-blind Phase

Inclusion Criteria:

  • Subjects must achieve consistent clinical stability, defined as total scores ≤ 12 on the YMRS and MADRS over at least 12 weeks, with the allowance of two excursions (YMRS and/or MADRS total scores up to 13 or 14, respectively) except during the last 4 weeks before randomization

Exclusion Criteria:

Open Label Phase

  • Diagnosis of an Axis I or Axis II disorder, other than bipolar I disorder, that is the primary focus of treatment within 3 months of screening
  • Subjects for whom diagnostic agreement between the Investigator and United BioSource Corporation (Boston) (UBC) cannot be reached
  • Ultra-fast rapid cycling (defined as ≥ 8 mood episodes over the previous 12-month period)
  • Subjects who test positive for drugs of abuse at screening. In the event a subject tests positive for cannabinoids (tetrahydrocannabinol), the Investigator will evaluate the subject's ability to abstain from cannabis during the study
  • Unstable/inadequately treated medical illness
  • The subjects answers "yes" to "Suicidal Ideation" items 4 or 5 on the C-SSRS (at time of evaluation)

Double Blind Phase

  • Subjects who in the Investigator's judgment have not been compliant with study medication during the stabilization phase
  • Subjects who have not stabilized during the open-label phase (within 20 weeks)
  • Subjects who test positive for drugs of abuse at double-blind phase baseline. In the event a subject tests positive for cannabinoids (tetrahydrocannabinol), the Investigator will evaluate the subject's ability to abstain from cannabis during the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
965 participants (actual)

Study arms

  • Experimental
    Lurasidone 20-80 mg flexible dose

    Drug: Lurasidone

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Lurasidone 20 mg daily (days 1-3), Lurasidone 40 mg daily (days 4-7), Lurasidone 20-80 mg daily (flexible dose) thereafter

  • DrugPlacebo

    20-80 mg flexible dose

06

What researchers measure

Primary outcomes

  1. Time to Recurrence of Mood Event During the Double Blind Treatment Phase

    A mood event is defined as one of the following during the double-blind phase: (1) Fulfilled Diagnostic and Statistical Manual of Mental Disorders, 4th Ed., Text Revision (DSM-IV-TR) criteria for manic, mixed manic, hypomanic, or depressive episode. (2) Required treatment intervention for manic, mixed manic, hypomanic, or depressive symptoms with any antipsychotic (other than study drug), antidepressant, mood stabilizer (other than lithium or divalproex), anxiolytic agents, benzodiazepine (beyond dosage allowed for anxiety, agitation, or insomnia). (3) Psychiatric hospitalization for any bipolar mood episode. (4) Young Mania Rating Scale (YMRS) or Montgomery-Asberg Depression Rating Scale (MADRS) total score ≥ 18 or Clinical Global Impression Bipolar Version, Severity of Illness (CGI BP S) score ≥ 4 at 2 consecutive assessments no more than 10 days apart. (5) Discontinuation from the study because of a mood event (as determined by the Investigator).

    Time frame: 28 weeks (up to 33 weeks)

Secondary outcomes

  1. Time to All-cause Discontinuation

    Time frame: 28 weeks (up to 33 weeks)

  2. Time to Recurrence of a Manic, Mixed Manic, Hypomanic, or Depressed Episode

    Time frame: 28 weeks (up to 33 weeks)

  3. Percentage of Subjects Who Experience a Recurrence of a Manic, Mixed Manic, Hypomanic, or Depressed Episode

    Time frame: 28 weeks

  4. Change From Double-blind Baseline to Week 28 (LOCF) in CGI-BP-S Overall Score

    The CGI-BP-S overall score is a single value, clinician-rated assessment of overall bipolar illness severity and ranges from 1=Normal, not at all ill, to 7=Among the most extremely ill patients. a higher score is associated with greater illness severity.

    Time frame: Double-blind Baseline to week 28

  5. Change From Double -Blind Baseline to Week 28 (LOCF) in CGI-BP-S Mania Score

    The CGI-BP-S mania score is a single value, clinician-rated assessment of mania illness severity and ranges from 1=Normal, not at all ill to 7=Among the most extremely ill patients. A high score is associated with greater illness severity

    Time frame: Double-blind Baseline to week 28

  6. Change From Double-blind Baseline to Week 28 (LOCF) in CGI+-BP-S Depression Score

    The CGI-BP-S depression score is a single value, clinician-rated assessment of depression illness severity and ranges from 1=Normal, not at all ill to 7=Among the most extremely ill patients. A higher score is associated with a greater illness severity.

    Time frame: Double-blind Baseline to week 28

  7. Change From Double-blind Baseline to Week 28 (LOCF) in YMRS Total Score

    the YMRS is an 11-item instrument used to assess the severity of mania in subjects with a diagnosis of bipolar disorder. Ratings are based on patient self-reporting, combined with clinician observation (accorded greater score). The YMRS total score is calculated as the sum of the 11 items. The YMRS total score ranges from 0 to 60. Higher scores are associated with greater severity of maia.

    Time frame: Double-blind Baseline to week 28

  8. Change From Double-blind Baseline to Week 28 (LOCF) in MADRS Total Score

    The MADRS consists of 10 items, each rated on a Likert scale, from 0=Normal to 6=Most Severe. The MADRS total score is calculated as the sum of the 10 items. The MADRS total score ranges from 0 to 60. Higher scores are associated with greater severity of depressive symptoms.

    Time frame: Double-blind Baseline to week 28

  9. Change Fro Double-blind Baseline to Week 28 (LOCF) in QIDS-SR(16) Total Score

    The QIDS-SR16 is a 16-item self-report measure of depressive symptomatology which uses a computerized assessment interface for administration. The scoring system for the QIDS-SR16 converts responses to 16 separate items into nine DSM-IV symptom criterion domains. The nine domains comprise: depressed mood (Item 5); concentration/decision making (Item 10); self outlook (Item 11); suicidal ideation (Item 12); decreased interest (Item 13); decreased energy (Item 14); sleep disturbance (initial, middle, and late insomnia or hypersomnia) (highest score of Items 1 to 4); appetite/weight disturbance (highest score of Items 6 to 9); and psychomotor disturbance (highest score of Items 15 and 16). The QIDS-SR16 total score is calculated as the sum of the 9 domain scores. The QIDS-SR16 total score ranges from 0 to 27 with a high score indicating more severe symptoms.

    Time frame: Double-blind Baseline to week 28

  10. Change From Double-blind Baseline to Week 28 (LOF) in PANSS Positive Symptom (PANNS-P) Subscale Score

    The PANSS-P is a subset of items in the PANSS, an interview-based measure of the severity of psychopathology in adults with psychotic disorders. The measure contains seven questions to assess delusions, conceptual disorganization, hallucinations behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS-P subscale score is the sum of the 7 items and ranges from 7 through 49. A higher score is associated with greater illness severity.

    Time frame: Double-blind Baseline to week 28

  11. Change From Double-blind Baseline to Week 28 (LOCF) in SDS Total Score

    The SDS is a composite of three self-rated items designed to measure the extent to which three major sectors in the patient's life are impaired by depressive symptoms. The SDS total score is calculated as the sum of the 3 items. The SDS total score ranges from 0 to 30. Higher scores are associated with greater severity of global functional impairments. If a subject has not worked/studied at all during the past week for reasons unrelated to the disorder, the SDS total score will be set to missing.

    Time frame: Double-blind Baseline to week 28

  12. Change From Double-blind Baseline to Week 28 (LOCF) in PIRS-2 Total Score

    The PIRS-2 is a 2-item self-report of insomnia assessed via a computer interface. Each item is scored from 0-3. The PIRS-2 total score is calculated as the sum of the 2 items. The PIRS total score ranges from 0 to 6. Higher scores are associated with greater severity of insomnia.

    Time frame: Double-blind Baseline to week 28

  13. Change From Double-blind Baseline to Week 28 (LOCF) in Q-LES-Q-SF Percent Maximum Possible Score

    The Q-LES-Q-SF is a 16-item self-report measure of the degree of enjoyment and satisfaction in various areas of daily living. The questionnaire was developed and validated for use in depressed outpatient subjects and has eight summary scales that reflect major areas of functioning: physical health, mood, leisure time activities, social relationships, general activities, work, household duties and school/coursework. Each item is rated on a 5-point scale, ranging from 1 (very poor) to 5 (very good). The Q-LES-Q-SF percentage maximum possible score is calculated as 100 × (Raw Score - 14 \[Minimum Score\]) / (70 \[Maximum Score\] - 14 \[Minimum Score\]). Higher percent maximum scores indicate better quality of life.

    Time frame: Double-blind Baseline to week 28

07

Results

Posted Jul 26, 2016

Participant flow

Open Label Phase
Participant flow — Open Label Phase
MilestoneLurasidone 20-80 mg Flexible DosePlaceboAll Subjects
Started00965
Completed00503
Not completed00462
Withdrew: Adverse event0059
Withdrew: Lack of efficacy00107
Withdrew: Lost to follow-up0076
Withdrew: Protocol violation0045
Withdrew: Withdrawal by subject00112
Withdrew: Did not meet criteria for db phase0016
Withdrew: Terminated at study completion005
Withdrew: Mood episode0042
Double-Blind Phase
Participant flow — Double-Blind Phase
MilestoneLurasidone 20-80 mg Flexible DosePlaceboAll Subjects
Started2462500
Completed1661500
Not completed801000
Withdrew: Adverse event850
Withdrew: Lost to follow-up570
Withdrew: Protocol violation1110
Withdrew: Protocol violation16120
Withdrew: Terminated at study completion200
Withdrew: Recurrence of mood event48640
Withdrew: Administrative010

Outcome measures

PrimaryTime to Recurrence of Mood Event During the Double Blind Treatment Phase

A mood event is defined as one of the following during the double-blind phase: (1) Fulfilled Diagnostic and Statistical Manual of Mental Disorders, 4th Ed., Text Revision (DSM-IV-TR) criteria for manic, mixed manic, hypomanic, or depressive episode. (2) Required treatment intervention for manic, mixed manic, hypomanic, or depressive symptoms with any antipsychotic (other than study drug), antidepressant, mood stabilizer (other than lithium or divalproex), anxiolytic agents, benzodiazepine (beyond dosage allowed for anxiety, agitation, or insomnia). (3) Psychiatric hospitalization for any bipolar mood episode. (4) Young Mania Rating Scale (YMRS) or Montgomery-Asberg Depression Rating Scale (MADRS) total score ≥ 18 or Clinical Global Impression Bipolar Version, Severity of Illness (CGI BP S) score ≥ 4 at 2 consecutive assessments no more than 10 days apart. (5) Discontinuation from the study because of a mood event (as determined by the Investigator).

Time frame:
28 weeks (up to 33 weeks)
Reported as:
Median · Days
Time to Recurrence of Mood Event During the Double Blind Treatment Phase
DaysLurasidone 20-80 mg Flexible DosePlacebo
Time to Recurrence of Mood Event During the Double Blind Treatment PhaseNA (NA to NA)207 (207 to NA)
Statistical analysis
  • Lurasidone 20-80 mg Flexible Dose vs Placebo · Cox Proportional Hazards Model · p = <0.078 (A hazard ratio of time to recurrence and its corresponding 95% Wald CI were estimated for the lurasidone arm vs.placebo arm, using a Cox proportional hazards model.Cox model included treatment effect as fixed effect, and stratified by pooled country.) · Hazard ratio (hr): 0.71 · 95% CI 0.49 to 1.04
SecondaryTime to All-cause Discontinuation
Time frame:
28 weeks (up to 33 weeks)
Reported as:
Median · Days
Time to All-cause Discontinuation
DaysLurasidone 20-80 mg Flexible DosePlacebo
Time to All-cause Discontinuation225 (204 to 233)207 (207 to 216)
Statistical analysis
  • Lurasidone 20-80 mg Flexible Dose vs Placebo · Cox Proportional Hazards Model · p = <0.034 (A HR of time to discontinuation and corresponding 95% Wald CI were est. for lurasidone arm vs.the placebo arm, using a Cox proportional hazards model. Model included treatment effect including treatment as a fixed effect,stratified by pooled country.) · Cox proportional hazard: 0.72 · 95% CI 0.54 to 0.98
SecondaryTime to Recurrence of a Manic, Mixed Manic, Hypomanic, or Depressed Episode
Time frame:
28 weeks (up to 33 weeks)
Reported as:
Median · Days
Time to Recurrence of a Manic, Mixed Manic, Hypomanic, or Depressed Episode
DaysLurasidone 20-80 mg Flexible DosePlacebo
Time to Recurrence of a Manic, Mixed Manic, Hypomanic, or Depressed EpisodeNA (NA to NA)NA (207 to NA)
Statistical analysis
  • Lurasidone 20-80 mg Flexible Dose vs Placebo · Cox Proportional hazard Model · p = 0.113 (A HR of time to recurrence and its corresponding 95% Wald CI were estimated for lurasidone arm vs. placebo arm,using a Cox proportional hazards model. Model included treatment effect including treatment as a fixed effect stratified by pooled country.) · Cox proportional hazard: 0.72 · 95% CI 0.48 to 1.08
SecondaryPercentage of Subjects Who Experience a Recurrence of a Manic, Mixed Manic, Hypomanic, or Depressed Episode
Time frame:
28 weeks
Reported as:
Number · percentage of participants
Percentage of Subjects Who Experience a Recurrence of a Manic, Mixed Manic, Hypomanic, or Depressed Episode
percentage of participantsLurasidone 20-80 mg Flexible DosePlacebo
Percentage of Subjects Who Experience a Recurrence of a Manic, Mixed Manic, Hypomanic, or Depressed Episode16.721.6
SecondaryChange From Double-blind Baseline to Week 28 (LOCF) in CGI-BP-S Overall Score

The CGI-BP-S overall score is a single value, clinician-rated assessment of overall bipolar illness severity and ranges from 1=Normal, not at all ill, to 7=Among the most extremely ill patients. a higher score is associated with greater illness severity.

Time frame:
Double-blind Baseline to week 28
Reported as:
Least squares mean · units on a scale
Change From Double-blind Baseline to Week 28 (LOCF) in CGI-BP-S Overall Score
units on a scaleLurasidone 20-80 mg Flexible DosePlacebo
Change From Double-blind Baseline to Week 28 (LOCF) in CGI-BP-S Overall Score0.40 ± 0.0850.49 ± 0.085
Statistical analysis
  • Lurasidone 20-80 mg Flexible Dose vs Placebo · ANCOVA · p = 0.406 (analysis of ANCOVA model contains treatment ,pooled country, and mood stabilizer (lithium or divalproex) as fixed factors and baseline as a covariate.) · Ls mean difference lurasidone vs.placebo: -0.09 · 95% CI -0.29 to 0.12
SecondaryChange From Double -Blind Baseline to Week 28 (LOCF) in CGI-BP-S Mania Score

The CGI-BP-S mania score is a single value, clinician-rated assessment of mania illness severity and ranges from 1=Normal, not at all ill to 7=Among the most extremely ill patients. A high score is associated with greater illness severity

Time frame:
Double-blind Baseline to week 28
Reported as:
Least squares mean · units on a scale
Change From Double -Blind Baseline to Week 28 (LOCF) in CGI-BP-S Mania Score
units on a scaleLurasidone 20-80 mg Flexible DosePlacebo
Change From Double -Blind Baseline to Week 28 (LOCF) in CGI-BP-S Mania Score0.10 ± 0.0620.21 ± 0.062
Statistical analysis
  • Lurasidone 20-80 mg Flexible Dose vs Placebo · ANCOVA · p = 0.162 (Analysis of Covariance (ANCOVA) model contains treatment, and pooled country, and mood stabilizer (lithium or divalproex) as fixed factors and baseline as a covariate.) · Ls mean difference lurasidone vs.placebo: -0.11 · 95% CI -0.26 to 0.04
SecondaryChange From Double-blind Baseline to Week 28 (LOCF) in CGI+-BP-S Depression Score

The CGI-BP-S depression score is a single value, clinician-rated assessment of depression illness severity and ranges from 1=Normal, not at all ill to 7=Among the most extremely ill patients. A higher score is associated with a greater illness severity.

Time frame:
Double-blind Baseline to week 28
Reported as:
Least squares mean · units on a scale
Change From Double-blind Baseline to Week 28 (LOCF) in CGI+-BP-S Depression Score
units on a scaleLurasidone 20-80 mg Flexible DosePlacebo
Change From Double-blind Baseline to Week 28 (LOCF) in CGI+-BP-S Depression Score0.35 ± 0.0820.42 ± 0.081
Statistical analysis
  • Lurasidone 20-80 mg Flexible Dose vs Placebo · ANCOVA · p = 0.496 (Analysis of covariance (ANCOVA) model contains treatment, and pooled country, and mood stabilizer (lithium or divalproex) as fixed factors and baseline as a covariate.) · Ls mean difference lurasidone vs.placebo: -0.07 · 95% CI -0.27 to 0.13
SecondaryChange From Double-blind Baseline to Week 28 (LOCF) in YMRS Total Score

the YMRS is an 11-item instrument used to assess the severity of mania in subjects with a diagnosis of bipolar disorder. Ratings are based on patient self-reporting, combined with clinician observation (accorded greater score). The YMRS total score is calculated as the sum of the 11 items. The YMRS total score ranges from 0 to 60. Higher scores are associated with greater severity of maia.

Time frame:
Double-blind Baseline to week 28
Reported as:
Least squares mean · units on a scale
Change From Double-blind Baseline to Week 28 (LOCF) in YMRS Total Score
units on a scaleLurasidone 20-80 mg Flexible DosePlacebo
Change From Double-blind Baseline to Week 28 (LOCF) in YMRS Total Score1.0 ± 0.431.8 ± 0.43
Statistical analysis
  • Lurasidone 20-80 mg Flexible Dose vs Placebo · ANCOVA · p = 0.128 (Analysis of Covariance (ANCOVA) model contains treatment, and pool country, and mood stabilizer (lithium or divalproex) as fixed factors and baseline as a covariate.) · Ls mean difference: -0.8 · 95% CI -1.8 to 0.2
SecondaryChange From Double-blind Baseline to Week 28 (LOCF) in MADRS Total Score

The MADRS consists of 10 items, each rated on a Likert scale, from 0=Normal to 6=Most Severe. The MADRS total score is calculated as the sum of the 10 items. The MADRS total score ranges from 0 to 60. Higher scores are associated with greater severity of depressive symptoms.

Time frame:
Double-blind Baseline to week 28
Reported as:
Least squares mean · units on a scale
Change From Double-blind Baseline to Week 28 (LOCF) in MADRS Total Score
units on a scaleLurasidone 20-80 mg Flexible DosePlacebo
Change From Double-blind Baseline to Week 28 (LOCF) in MADRS Total Score3.0 ± 0.573.5 ± 0.57
Statistical analysis
  • Lurasidone 20-80 mg Flexible Dose vs Placebo · ANCOVA · p = 0.485 (Analysis of Covariance (ANCOVA) model contains treatment, and pooled country, and mood stabilizer (lithium or divalproex) as fixed factors and baseline as a covariate.) · Ls mean difference lurasdione vs.placebo: -0.5 · 95% CI -1.9 to 0.9
SecondaryChange Fro Double-blind Baseline to Week 28 (LOCF) in QIDS-SR(16) Total Score

The QIDS-SR16 is a 16-item self-report measure of depressive symptomatology which uses a computerized assessment interface for administration. The scoring system for the QIDS-SR16 converts responses to 16 separate items into nine DSM-IV symptom criterion domains. The nine domains comprise: depressed mood (Item 5); concentration/decision making (Item 10); self outlook (Item 11); suicidal ideation (Item 12); decreased interest (Item 13); decreased energy (Item 14); sleep disturbance (initial, middle, and late insomnia or hypersomnia) (highest score of Items 1 to 4); appetite/weight disturbance (highest score of Items 6 to 9); and psychomotor disturbance (highest score of Items 15 and 16). The QIDS-SR16 total score is calculated as the sum of the 9 domain scores. The QIDS-SR16 total score ranges from 0 to 27 with a high score indicating more severe symptoms.

Time frame:
Double-blind Baseline to week 28
Reported as:
Least squares mean · units on a scale
Change Fro Double-blind Baseline to Week 28 (LOCF) in QIDS-SR(16) Total Score
units on a scaleLurasidone 20-80 mg Flexible DosePlacebo
Change Fro Double-blind Baseline to Week 28 (LOCF) in QIDS-SR(16) Total Score0.9 ± 0.271.1 ± 0.27
Statistical analysis
  • Lurasidone 20-80 mg Flexible Dose vs Placebo · ANCOVA · p = 0.582 (Analysis of Covariance (ANCOVA) model contains treatment, and pooled country, and mood stabilizer (lithium or divalproex) as fixed factors and baseline as a covariate.) · Ls mean difference: -0.2 · 95% CI -0.8 to 0.5
SecondaryChange From Double-blind Baseline to Week 28 (LOF) in PANSS Positive Symptom (PANNS-P) Subscale Score

The PANSS-P is a subset of items in the PANSS, an interview-based measure of the severity of psychopathology in adults with psychotic disorders. The measure contains seven questions to assess delusions, conceptual disorganization, hallucinations behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS-P subscale score is the sum of the 7 items and ranges from 7 through 49. A higher score is associated with greater illness severity.

Time frame:
Double-blind Baseline to week 28
Reported as:
Least squares mean · units on a scale
Change From Double-blind Baseline to Week 28 (LOF) in PANSS Positive Symptom (PANNS-P) Subscale Score
units on a scaleLurasidone 20-80 mg Flexible DosePlacebo
Change From Double-blind Baseline to Week 28 (LOF) in PANSS Positive Symptom (PANNS-P) Subscale Score0.2 ± 0.130.3 ± 0.13
Statistical analysis
  • Lurasidone 20-80 mg Flexible Dose · ANCOVA · p = 0.420 (Analysis of Covariance (ANCOVA) model contains treatment, and pooled country, and mood stabilizer (lithium or divalproex) as fixed factors and baseline as a covariate.) · Ls mean difference lurasidone vs.placebo: -0.01 · 95% CI -0.5 to 0.2
SecondaryChange From Double-blind Baseline to Week 28 (LOCF) in SDS Total Score

The SDS is a composite of three self-rated items designed to measure the extent to which three major sectors in the patient's life are impaired by depressive symptoms. The SDS total score is calculated as the sum of the 3 items. The SDS total score ranges from 0 to 30. Higher scores are associated with greater severity of global functional impairments. If a subject has not worked/studied at all during the past week for reasons unrelated to the disorder, the SDS total score will be set to missing.

Time frame:
Double-blind Baseline to week 28
Reported as:
Least squares mean · units on a scale
Change From Double-blind Baseline to Week 28 (LOCF) in SDS Total Score
units on a scaleLurasidone 20-80 mg Flexible DosePlacebo
Change From Double-blind Baseline to Week 28 (LOCF) in SDS Total Score0.4 ± 0.590.6 ± 0.61
Statistical analysis
  • Lurasidone 20-80 mg Flexible Dose vs Placebo · ANCOVA · p = 0.788 (Analysis of Covariance (ANCOVA) model contains treatment, and pooled country, and mood stabilizer (lithium or divalproex) as fixed factors and baseline as a covariate.) · Ls mean difference lurasidone vs.placebo: -0.2 · 95% CI -1.6 to 1.2
SecondaryChange From Double-blind Baseline to Week 28 (LOCF) in PIRS-2 Total Score

The PIRS-2 is a 2-item self-report of insomnia assessed via a computer interface. Each item is scored from 0-3. The PIRS-2 total score is calculated as the sum of the 2 items. The PIRS total score ranges from 0 to 6. Higher scores are associated with greater severity of insomnia.

Time frame:
Double-blind Baseline to week 28
Reported as:
Least squares mean · units on a scale
Change From Double-blind Baseline to Week 28 (LOCF) in PIRS-2 Total Score
units on a scaleLurasidone 20-80 mg Flexible DosePlacebo
Change From Double-blind Baseline to Week 28 (LOCF) in PIRS-2 Total Score0.4 ± 0.100.5 ± 0.10
Statistical analysis
  • Lurasidone 20-80 mg Flexible Dose vs Placebo · ANCOVA · p = 0.380 (Analysis of Covariance (ANCOVA) model contains treatment, and pooled country, and mood stabilizer (lithium or divalproex) as fixed factors and baseline as a covariate.) · Ls mean difference lurasidone vs.placebo: -0.1 · 95% CI -0.3 to 0.1
SecondaryChange From Double-blind Baseline to Week 28 (LOCF) in Q-LES-Q-SF Percent Maximum Possible Score

The Q-LES-Q-SF is a 16-item self-report measure of the degree of enjoyment and satisfaction in various areas of daily living. The questionnaire was developed and validated for use in depressed outpatient subjects and has eight summary scales that reflect major areas of functioning: physical health, mood, leisure time activities, social relationships, general activities, work, household duties and school/coursework. Each item is rated on a 5-point scale, ranging from 1 (very poor) to 5 (very good). The Q-LES-Q-SF percentage maximum possible score is calculated as 100 × (Raw Score - 14 \[Minimum Score\]) / (70 \[Maximum Score\] - 14 \[Minimum Score\]). Higher percent maximum scores indicate better quality of life.

Time frame:
Double-blind Baseline to week 28
Reported as:
Least squares mean · units on a scale
Change From Double-blind Baseline to Week 28 (LOCF) in Q-LES-Q-SF Percent Maximum Possible Score
units on a scaleLurasidone 20-80 mg Flexible DosePlacebo
Change From Double-blind Baseline to Week 28 (LOCF) in Q-LES-Q-SF Percent Maximum Possible Score-1.70 ± 1.022-2.07 ± 1.035
Statistical analysis
  • Lurasidone 20-80 mg Flexible Dose vs Placebo · ANCOVA · p = 0.772 (Analysis of Covariance (ANCOVA) model contains treatment, and pooled country, and mood stabilizer (lithium or divalproex) as fixed factors and baseline as a covariate.) · Ls mean difference lurasidone vs.placebo: 0.37 · 95% CI -2.14 to 2.88

Adverse events

Collected over For all subjects column: during open label phase (up to 20 weeks) For 7 lurasidone + Li/VPA and placebo +Li/VPA columns: during double blind phase (up to 28 weeks).. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lurasidone 20-80 mg Flexible Dose—13/246 (5.3%)81/246 (32.9%)
Placebo—11/250 (4.4%)81/250 (32.4%)
All Subjects—41/962 (4.3%)474/962 (49.3%)
Most frequent serious events
Showing 10 of 47
Most frequent serious events
EventLurasidone 20-80 mg Flexible DosePlaceboAll Subjects
ManiaPsychiatric disorders2/2463/2505/962
DepressionPsychiatric disorders2/2461/25010/962
Suicidal IdeationPsychiatric disorders2/2460/2502/962
Bipolar 1 DisorderPsychiatric disorders1/2462/2502/962
CholelithiasisHepatobiliary disorders1/2461/2500/962
AppendicitisInfections and infestations1/2460/2500/962
HypokalaemiaMetabolism and nutrition disorders1/2460/2500/962
Bipolar DisorderPsychiatric disorders1/2460/2500/962
Intentional Self InjuryPsychiatric disorders1/2460/2500/962
Suicide AttemptPsychiatric disorders1/2460/2502/962
Most frequent other events
Showing 10 of 15
Most frequent other events
EventLurasidone 20-80 mg Flexible DosePlaceboAll Subjects
NauseaGastrointestinal disorders0/2460/250111/962
Weight IncreasedInvestigations24/24613/2500/962
HeadacheNervous system disorders21/24617/25088/962
AkathisiaNervous system disorders9/2468/25080/962
InsomniaPsychiatric disorders9/24616/25077/962
SomnolenceNervous system disorders0/2464/25069/962
VomitingGastrointestinal disorders0/2460/25059/962
NasopharyngitisInfections and infestations15/24612/25039/962
TremorNervous system disorders15/24611/25043/962
DiarrhoeaGastrointestinal disorders0/2460/25053/962

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Lurasidone 20-80 mg Flexible DosePlaceboTotal
<=18 years202
Between 18 and 65 years232242474
>=65 years12820
Age, Continuous
Age, Continuous(years)Lurasidone 20-80 mg Flexible DosePlaceboTotal
Mean45.7 ± 12.4343.2 ± 12.1844.4 ± 12.36
Sex: Female, Male
Sex: Female, Male(Participants)Lurasidone 20-80 mg Flexible DosePlaceboTotal
Female136143279
Male110107217
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Lurasidone 20-80 mg Flexible DosePlaceboTotal
Hispanic or Latino413879
Not Hispanic or Latino205212417
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Lurasidone 20-80 mg Flexible DosePlaceboTotal
American Indian or Alaska Native022
Asian6713
Native Hawaiian or Other Pacific Islander000
Black or African American232144
White213216429
More than one race000
Unknown or Not Reported448
Region of Enrollment
Region of Enrollment(participants)Lurasidone 20-80 mg Flexible DosePlaceboTotal
Argentina191938
Russian Federation303161
Hungary131528
United States7376149
Japan5510
Czech Republic232447
Poland222143
Slovakia437
Bulgaria202040
Chile91120
France8614
Serbia201939
08

Study locations

105 sites
  • Harmonex Neuroscience Research
    Dothan, Alabama 36303, United States
  • Behavioral Research Specialists, LLC
    Glendale, California 91206, United States
  • AXIS Clinical Trials
    Los Angeles, California 90036, United States
  • Excell Research, Inc.
    Oceanside, California 92056, United States
  • Stanford University School of Medicine Research Program VA Palo Alto Health Care System
    Palo Alto, California 94304, United States
  • SF-CARE, Inc.
    San Francisco, California 94117, United States
  • Neuropsychiatric Research Center of Orange County
    Santa Ana, California 92701, United States
  • "Stanford University School of Medicine
    Stanford, California 94305, United States
  • Florida Clinical Research LLC
    Bradenton, Florida 34201, United States
  • Clinical Neuroscience Solutions, Inc.
    Jacksonville, Florida 32216, United States
  • Galiz Research
    Miami Springs, Florida 33166, United States
  • Clinical Neuroscience Solutions
    Orlando, Florida 32806, United States
  • Atlanta Center for Medical Research
    Atlanta, Georgia 30308, United States
  • Clinco
    Terre Haute, Indiana 47802, United States
  • ActivMed Practices & Research Inc.
    Haverhill, Massachusetts 08130, United States
  • Psych Care Consultants Research
    St. Louis, Missouri 63128, United States
  • Village Clinical Research Inc,
    New York, New York 10003, United States
  • Finger Lakes Clinical Research
    Rochester, New York 14618, United States
  • Charak Center for Health and Wellness
    Garfield Heights, Ohio 44125, United States
  • Cutting Edge Research Groupd
    Oklahoma City, Oklahoma 73116, United States
  • Suburban Research Associates
    Media, Pennsylvania 19063, United States
  • Lincoln Research
    Lincoln, Rhode Island 02865, United States
  • Carolina Clinical Trials, Inc.
    Charleston, South Carolina 29407, United States
  • Clinical Neuroscience Solutions Inc.
    Memphis, Tennessee 38119, United States
  • Psychoneuroendocrinology Research Group, Dept of Psychiatry, UT Southwestern Medical Center
    Dallas, Texas 75235, United States
  • R/D Clinical Research, Inc.
    Lake Jackson, Texas 77566, United States
  • Sanatorio Morra
    Cordoba, Provincia de Cordoba 5009, Argentina
  • Centro de Atencion E Invest. Clinica (CAICI)
    Rosario, Santa Fe 2000, Argentina
  • Novain Neurociencias Group
    Buenos Aires, C1117ABH, Argentina
  • Centro de Neuropsiquiatria
    Buenos Aires, C1425AHQ, Argentina
  • IPEM-Instituto de Prevención de las Enfermedades Mentales.
    Buenos Aires, Argentina
  • Instituto DAMCI
    Cordoba, 5009, Argentina
  • Clinica Privada de Salud Mental Santa Teresa de Avila
    La Plata, 1900, Argentina
  • Centro de Psiquiatria Biologica
    Mendoza, 5500, Argentina
  • The Lyell McEwin Hospital
    Elizabeth Vale, South Australia 5112, Australia
  • RWF Medic Pty Ltd as Trustee for Farnbach Family Trust at Neurotherapy Victoria
    Malvern, Victoria 3144, Australia
  • The Melbourne Clinic
    Richmond, Victoria 3121, Australia
  • Hollywood Medical Centre
    Fremantle, Western Australia 6160, Australia
  • Psychiatry Dispensary
    Bourgas, 80000, Bulgaria
  • University Multiprofiled Hospital for Active Treatment "Sveti Georgi"
    Plovdiv, 4002, Bulgaria
  • Regional Psychiatric Dispensary
    Rousse, 7003, Bulgaria
  • Multiprofiled Hospital for Active Treatment "Alexandrovska"
    Sofia, 1431, Bulgaria
  • Psychiatric Clinic, Military Medical Academy
    Sofia, 1606, Bulgaria
  • Multprofiled Hospital for Active Treatment "Sveta Marina"
    Varna, 9010, Bulgaria
  • CETEP
    Santiago, 27014, Chile
  • Clinica Las Condes
    Santiago, 27014, Chile
  • Psicomedica
    Santiago, 27014, Chile
  • Clinic Hospital Centre Rijeka Clinic for Psychiatry
    Rijeka, 51000, Croatia
  • Clinical Hospital Centre Zagreb
    Zagreb, 10000, Croatia
  • Klinicki Bolnicki Centar Zagreb-Rebro
    Zagreb, 10000, Croatia
  • University Hospital Sestremilosrdnice
    Zagreb, Croatia
  • University Hospital Centre Zagreb
    Zagreg, 10000, Croatia
  • Fakultni Nemocnice Brno
    Brno-Bohunice, 62500, Czech Republic
  • Saint Anne s.r.o.
    Brno, 602 00, Czech Republic
  • Psychiatricka ambulance
    Havirov, 736 01, Czech Republic
  • Psychiatricka Iecebna U Honzicka
    Pisek, 397 01, Czech Republic
  • Psychiatricke Centrum Praha
    Prague 8-Bohunice, 62500, Czech Republic
  • Psychiatricka Ambulance
    Prague, 10600, Czech Republic
  • Clintrial s.r.o.
    Praha 10, 100 00, Czech Republic
  • Psychiatricka ambulance Prosek
    Praha 3, 190 00, Czech Republic
  • Psychiaricka ambulance
    Praha 4, 140 00, Czech Republic
  • Psychosocialni Centrum
    Prerov, 75001, Czech Republic
  • Psychiatricka ambulance
    Usti nad labem, 401 13, Czech Republic
  • CHS La Chartreuse-Pole 6
    Dijon cedex, 21033, France
  • Centre Hospitalier Specialise du Jura-Centre Medico Psychiatrique
    Dole, 39100, France
  • Hopital Lapeyronie
    Montpellier Cedex 5, 34295, France
  • CHRU de Nimes, Service de Psychiatrie adulte
    Nimes Cedex 09, 30029, France
  • Obudai Egeszsegugyi Centurm Kft.
    Budapest, 1036, Hungary
  • Fovarosi Onkormanyzat Szent Istvan Korhaz es Szent Laszlo Korhaz
    Budapest, 1096, Hungary
  • Kutvolgyi Klinikai Tomb SOTE IIIsz Belgyogyaszati Klinika
    Budapest, 1125, Hungary
  • Nyiro Gyula Korhaz
    Budapest, 1135, Hungary
  • Fovarosi Onkormanyzat Nyiro Gyula Korhaz, I. Pszichiatria
    Budapest, H-1135, Hungary
  • Petz Aladar Megyei Oktato Korhaz
    Gyor, 9024, Hungary
  • Bekes Megyei Kepviselotestulet Pandy Kalman Korhaz
    Gyula, 5700, Hungary
  • Haruna Hospital
    Shibukawa, Gunma, Japan
  • Goryokai Medical Corporation
    Sapporo-shi, Hokkaido 002-8029, Japan
  • Sapporokousetsu Hospital
    Sapporo, Hokkaido, Japan
  • Nagano Prefectural Mental Wellness Center-Komagane
    Komagane,, Nagano, Japan
  • Shonan Hospital
    Matsumoto-shi, Nagano 390-0847, Japan
  • Asakayama General Hospital
    Sakai, Osaka, Japan
  • National Hospital Organization Hizen Psychiatric Center
    Kanzaki, Saga 842-0192, Japan
  • Nishigahara Hospital
    Kita-ku, Tokyo 114-0024, Japan
  • Okehazama Hospital Fujita Kokoro Care Center
    Aichi, 470-1168, Japan
  • Ongata Hospital
    Hachioji, Tokyo, Japan
  • Yuge Hospital
    Kumamoto, 861-8002, Japan
  • Arakaki Hospital
    Okinawa, 904-0012, Japan
  • Kawada Hospital
    Toyama, 933-0917, Japan
  • NZOZ Syntonia
    Gdynia, 81-361, Poland
  • NZOZ BioMed
    Kielce, 25411, Poland
  • Wojewodzki Osrodek Lexznictwa Psychiatrycznego w Toruniu
    Torun, 87-100, Poland
  • Prywatny Gabinet Lekarski Jaroslaw Strzelec
    Tuszyn, 95-080, Poland
  • Przychodnia Lekarsko-Psychologiczna "Persona" Spolka Partnerska Lekarzy
    Wroclaw, 50-227, Poland
  • State Healthcare and Forensic Psychiatric Expertise Institution
    Izhevsk, 462054, Russian Federation
  • Nizhny Novgorod Regional State Institution of Healthcare
    Nizhniy Novgorod, 603155, Russian Federation
  • St. Petersburg State Healthcare Institution (SPSHI)
    St. Petersburg, 190005, Russian Federation
  • St.Petersburg State Healthcare Institution (SPSHI)
    St. Petersburg, 190005, Russian Federation
  • St Petersburg State Government Healthcare Institution
    St. Petersburg, 190121, Russian Federation
  • Mental Health Research Institute of Rams
    Tomsk, 634050, Russian Federation
  • Clinical Centre of Serbia
    Belgrade, 11000, Serbia
  • Clinical Hospital Centre Dragisa Misovic
    Belgrade, 11000, Serbia

Showing the first 100 of 105 sites across 14 countries. Choose a country and city above to see the rest.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2011, a primary completion of Apr 2015 and a completion of Apr 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2016, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2011
First posted
May 23, 2011
Start
Jun 2011
Primary completionActual
Apr 2015
CompletionActual
Apr 2015
Results first posted
Jul 26, 2016
Last update
Sep 7, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 7, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01358357
Responsible party
Sponsor
First posted
May 23, 2011
Start date
Jun 2011
Primary completion
Apr 2015
Completion
Apr 2015
Results posted
Jul 26, 2016
Last update
Sep 7, 2016

Study contacts

Medical Director, MD
study director · Sumitomo Pharma America, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lurasidone

Start the discussion